Tau prion-like propagation: state of the art and current challenges
Abstract
It has been almost a decade since the hypothesis of active tau protein propagation in Alzheimer's disease and associated tauopathies was formally raised. We view tau propagation as a cascade of events, starting with early tau misfolding, followed by transfer to another, anatomically connected, cell, contaminating in corruption of endogenous tau in the recipient cell through a seeding mechanism of templated misfolding. These mechanisms are very similar to those of other proteinopathies and to ideas about how prion pathologies spread through the brain. Nonetheless, the specific mechanisms underlying each of these steps remains uncertain and is a fertile ground for new experimental approaches potentially requiring new experimental models. We review, here, the state of the art of the research on tau prion-like propagation and we highlight some key challenges to understanding the detailed mechanisms of cell to cell propagation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Short fibrils and oligomers of tau can transfer from one neuron to another and spread pathology throughout the brain in a prion-like manner.
“Over the past several years, it has become increasingly evident that short fibrils and oligomers of tau can transfer from one neuron to another and thereby spread pathology throughout the brain in a prion-like manner (4, 5, 6).”
From MAP2 caps tau fibrils and inhibits aggregation (2023) · cites this paper as [4]
The citation lists haven’t been fetched yet
References 162 · Cited by 84
- Authors
- Dujardin, S., & Hyman, B. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Hyman, Bradley T.
- Venue
- Advances in Experimental Medicine and Biology
- Publisher
- Springer Singapore
- Published
- 2019
- Volume
- 1184
- Pages
- 305-325
- ISSN
- 0065-2598 (ISSN-L)
- 2214-8019
- OpenAlex
- W3007822979
- Cited by
- 84
- References
- 162
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 11 · 2023: 17 · 2022: 9 · 2021: 15 · 2020: 13
- FWCI
- 28.32
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Advances in experimental medicine and biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (RF1AG059789, P30AG062421)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein, prion-like propagation, Alzheimer's disease, tauopathy, tau misfolding, cell-to-cell transmission, proteinopathies, experimental model
- MeSH terms
- Alzheimer Disease, Brain, Humans, Prions, tau Proteins, Tauopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review